Wave Life Sciences Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
WVE Nasdaq 2830 wavelifesciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Wave Life Sciences Ltd.

Wave Life Sciences (WVE) Stock Looks Cheap On Price But Expensive On Sales - Jul 23rd, 2026 3:14 pm
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026 - Jul 23rd, 2026 6:30 am
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock? - Jul 22nd, 2026 10:00 am
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - Jul 22nd, 2026 7:25 am
New Strong Buy Stocks for July 22nd - Jul 22nd, 2026 5:15 am
3 Promising Genomics Stocks to Add to Your Portfolio in 2026 - Jul 20th, 2026 8:49 am
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway - Jul 17th, 2026 12:25 pm
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last? - Jul 8th, 2026 7:47 am
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation - Jul 7th, 2026 2:15 pm
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect? - Jul 1st, 2026 7:55 am
Wave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM Trial - Jun 30th, 2026 10:34 am
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases - Jun 24th, 2026 6:30 am
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why - Jun 16th, 2026 10:00 am
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Jun 16th, 2026 6:43 am
Is Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now? - Jun 13th, 2026 2:45 pm
Wave Life Sciences to Present at Upcoming Investor Conferences - Jun 1st, 2026 6:30 am
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter - May 31st, 2026 2:16 pm
Should WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors? - May 25th, 2026 5:13 am
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update - May 20th, 2026 4:43 am
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 - May 19th, 2026 7:49 am